Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573065 | 0.77 | AHR (0.48) | AHRPIM1CUL4AACHEATM | |
| SCHEMBL31443280 | 0.77 | AHR (0.48) | AHRPIM1CUL4AACHEATM | |
| SCHEMBL32685459 | 0.75 | AHR (0.47) | AHRPIM1CUL4AACHEATM | |
| SCHEMBL9980173 | 0.74 | TSHR (0.35) | ATMLMNAMAPTHTT | |
| SCHEMBL30869472 | 0.72 | AHR (0.44) | AHRPIM1CUL4AACHEATM | |
| SCHEMBL13308132 | 0.71 | AHR (0.42) | AHRPIM1CUL4A | |
| SCHEMBL31314370 | 0.71 | ALDH1A1 (0.44) | AHRPIM1LMNAMAPT | |
| SCHEMBL2705505 | 0.71 | SLC1A3 (0.32) | PIM1 | |
| SCHEMBL15607139 | 0.70 | AHR (0.50) | AHRPIM1ATMMAPT | |
| SCHEMBL30869546 | 0.70 | MAPT (0.51) | AHRPIM1CUL4AATMCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | AHR 4553/4885PIM1 4177/4885CUL4A 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.